Skip to main content
. Author manuscript; available in PMC: 2018 Oct 10.
Published in final edited form as: Curr Probl Cancer. 2017 Oct 31;42(1):49–58. doi: 10.1016/j.currproblcancer.2017.10.004

Table 1.

Current immunotherapy clinical trials for advanced biliary tract tumors.

Clinical trial number Treatment regimen Phase Patients Trial status
NCT01174121 Adoptive immunotherapy with autologous tumor infiltrating lymphocytes following lymphocyte depletion plus pembrolizumab at progression II Metastatic GI tumors including cholangiocarcinoma Currently enrolling
NCT02982720 Pembrolizumab and PEG-intron II Advanced cholangiocarcinoma Not yet open for enrollment
NCT02834013 Nivolumab and ipilimumab II Advanced GI tumors including extrahepatic biliary carcinoma and intrahepatic cholangiocarcinoma Currently enrolling
NCT02923934 Ipilimumab and nivolumab II Advanced upper GI malignancies including cholangiocarcinoma Not yet open for enrollment
NCT02703714 Pembrolizumab and GM-CSF induction II Advanced biliary cancers Currently enrolling
NCT02628067 Pembrolizumab II Advanced solid tumors including BTC Currently enrolling
NCT02054806 Pembrolizumab I PDL1 positive advanced BTC Currently enrolling
NCT03111732 Pembrolizumab + capecitabine/oxaliplatin II Advanced BTC Not yet open for enrollment
NCT02821754 Durvalumab + tremelimumab + TACE/RFA or cryoablation I/II Advanced hepatocellular carcinoma and BTC Currently enrolling
NCT03101566 Nivolumab + gemcitabine/cisplatin or ipilimumab II Unresectable biliary tract cancer Not yet open for enrollment

GI, gastrointestinal.